{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"Pfizer acquisisce Amplyx Pharmaceuticals - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"AhIzzy4X7l\"><a href=\"https:\/\/frezzapartners.com\/en\/pfizer-acquisisce-amplyx-pharmaceuticals\/\">Pfizer acquisisce Amplyx Pharmaceuticals<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/pfizer-acquisisce-amplyx-pharmaceuticals\/embed\/#?secret=AhIzzy4X7l\" width=\"600\" height=\"338\" title=\"&#8220;Pfizer acquisisce Amplyx Pharmaceuticals&#8221; &#8212; Frezza Partners\" data-secret=\"AhIzzy4X7l\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/04\/pexels-michael-morse-1582736-scaled.jpg","thumbnail_width":2560,"thumbnail_height":1707,"description":"photo by Michael Morse &nbsp; Pfizer Inc. ha annunciato di aver acquisito Amplyx Pharmaceuticals, Inc., societ\u00e0 privata dedicata allo sviluppo di terapie per malattie debilitanti e pericolose per la vita che colpiscono persone con sistema immunitario compromesso. Il composto principale di Amplyx, Fosmanogepix (APX001), \u00e8 una nuova risorsa sperimentale in fase di sviluppo per il trattamento delle infezioni fungine invasive. Pi\u00f9 di 1,5 milioni di casi di infezioni fungine invasive si verificano in tutto il mondo ogni anno, con tassi..."}